Trial Protocol ID USOR 21501_V2000701_ENABLAR-2

Trial Description

A Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm in Combination with Abemaciclib (Enobosarm Combination Group) Compared to Estrogen Blocking Agent (Control Treatment Group) for the Second Line Treatment of ER+HER2- Metastatic Breast Cancer in Patients Who have Shown Previous Disease Progression on an Estrogen Blocking Agent Plus Palbociclib

Contact us regarding Clinical Trials at or call us at 877-664-7724


  • Jeanine L Werner, M.D.

Disease Types


  • Worldwide Clinical Trials NCT ID

  • NCT05065411